On January 27, 2016, Puma Biotechnology, Inc., through its legal counsel, responded to the Eshelman Letter, rejecting Eshelman's demands. In the letter, the Company stated that it stands by the truth of the statements contained in the investor presentation. In addition, the Company stated that if Eshelman persist in asserting baseless legal claims challenging the investor presentation, it will seek all available sanctions against Eshelman and Eshelman's counsel for the commencement and prosecution of meritless action.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.65 USD | -7.59% | +20.07% | -15.70% |
Jul. 01 | Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Completeness Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.70% | 176M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+43.96% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- PBYI Stock
- News Puma Biotechnology, Inc.
- Puma Biotechnology Responds to Fredric N. Eshelman’s Letter